Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Pharmacokinetics of multiple doses of Co-Crystal of Tramadol-Celecoxib: findings from a 4-way randomized open-label Phase I clinical trial.

Videla S, Lahjou M, Vaqué A, Sust M, Escriche M, Soler L, Sans A, Sicard E, Gascón N, Encina G, Plata-Salamán C.

Br J Clin Pharmacol. 2017 Sep 9. doi: 10.1111/bcp.13428. [Epub ahead of print]

PMID:
28888220
2.

Single-dose pharmacokinetics of Co-Crystal of Tramadol-Celecoxib: results of a 4-way randomized open-label Phase I clinical trial in healthy subjects.

Videla S, Lahjou M, Vaqué A, Sust M, Encabo M, Soler L, Sans A, Sicard E, Gascón N, Encina G, Plata-Salamán C.

Br J Clin Pharmacol. 2017 Aug 15. doi: 10.1111/bcp.13395. [Epub ahead of print]

PMID:
28810061
3.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.

PMID:
26762990
4.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group.

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

PMID:
26216031
5.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

6.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
7.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group.

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
8.

Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.

Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group.

HIV Med. 2014 Nov;15(10):595-603. doi: 10.1111/hiv.12162. Epub 2014 May 19.

9.

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.

Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group.

BMC Nephrol. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51.

10.

Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group.

BMC Infect Dis. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471.

11.

Associations between immune depression and cardiovascular events in HIV infection.

Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group.

AIDS. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3.

PMID:
23842128
12.

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group.

J Infect Dis. 2013 May 1;207(9):1359-69. doi: 10.1093/infdis/jit043. Epub 2013 Feb 4.

13.

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group.

J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426.

14.

Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies.

Abadias M, Escriche M, Vaqué A, Sust M, Encina G.

Br J Clin Pharmacol. 2013 Jan;75(1):103-17. doi: 10.1111/j.1365-2125.2012.04333.x.

15.

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group.

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.

PMID:
20543702
16.

High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome.

Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group.

AIDS. 2010 Jan 28;24(3):427-35. doi: 10.1097/QAD.0b013e328334344e.

PMID:
19910787
17.

Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex.

Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, Bruguera M, Hallal H, Robles-Diaz M, Rodriguez-González JF, Navarro JM, Salmeron J, Martinez-Odriozola P, Pérez-Alvarez R, Borraz Y, Hidalgo R; Spanish Group for the Study of Drug-Induced Liver Disease.

Hepatology. 2009 Jun;49(6):2001-9. doi: 10.1002/hep.22895.

PMID:
19475693
18.

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.

AIDS. 2008 Oct 18;22(16):2143-53. doi: 10.1097/QAD.0b013e3283112b77.

19.

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.

Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD.

Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862.

20.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD.

Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Erratum in: Lancet. 2008 Jul 26;372(9635):292.

Supplemental Content

Loading ...
Support Center